MORRISTOWN, N.J., Sept. 26, 2019 /PRNewswire/ -- Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with
ONZETRA® Xsail® provides a 22mg dose, dry powder formulation of sumatriptan, administered via a breath powered exhalation delivery system and is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults with or without aura.
"Despite the recent advances in migraine therapy, many patients still suffer debilitating migraine pain and are dissatisfied with their current treatments," said Stewart Tepper, MD professor of Neurology, Geisel School of Medicine at Dartmouth. "The Xsail® Breath Powered delivery device allows the medication to be deposited deep into the nose, an area that is rich with blood vessels. By delivering sumatriptan here, ONZETRA® Xsail® provides targeted and efficient delivery with the potential for fast relief."
"We are pleased to announce our first acquisition so early in the lifecycle of our company," said George Hampton, chief executive officer at Currax Pharmaceuticals LLC. "This acquisition is in line with both our focus to create greater patient access to life changing medicines and our business growth strategy to acquire underappreciated and clinically differentiated medicines."
ONZETRA® Xsail® was approved by FDA on January 28, 2016.
About Currax Pharmaceuticals LLC Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the US market. Currax distributes a range of both Branded and generic pharmaceutical products, including Silenor®, Treximet®, Zohydro® ER with BeadTek®, the authorized generic of Treximet®, and now ONZETRA® Xsail®.
About ONZETRA® Xsail® ONZETRA® Xsail® is a prescription medication approved for the acute treatment of migraine, with or without aura in adults. ONZETRA® Xsail® is used for people who have been told by a healthcare provider that they have migraine headaches. ONZETRA® Xsail® is not for the prevention of migraines or for other types of headaches, including cluster headache.
Important Safety Information ONZETRA® Xsail® may cause serious side effects, including:
Contact: George Jones, firstname.lastname@example.org, 862 579 2504
View original content:http://www.prnewswire.com/news-releases/currax-pharmaceuticals-llc-announces-first-acquisition-acquires-north-american-rights-to-onzetra-xsail-300926068.html
SOURCE Currax Pharmaceuticals LLC
Subscribe to our Free Newsletters!